Original vs. generic plerixafor for the mobilization of stem cells in multiple myeloma patients

Basit Öğe Kaydı
dc.contributor.authorYiğit Kaya, Süreyya
dc.contributor.authorMutlu, Yaşa Gül
dc.contributor.authorYücel, Orhan Kemal
dc.contributor.authorNizam Özen, İlknur
dc.contributor.authorAtaş, Ünal
dc.contributor.authorMelek, Elif
dc.contributor.authorMaral, Senem
dc.contributor.authorKarakuş, Volkan
dc.contributor.authorKaynar, Leylagül
dc.contributor.authorSevindik, Ömür Gökmen
dc.date.accessioned2025-05-28T16:47:29Z
dc.date.available2025-05-28T16:47:29Z
dc.date.issued2025
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractThis study investigates the efficacy and safety of generic plerixafor (Pleksor – Gen Pharma) compared to the original plerixafor (Mozobil - Sanofi) in patients with multiple myeloma undergoing ASCT. A total of 59 patients from three centers, who underwent ASCT between 2018 and 2023, were included and divided into two groups: Mozobil (M) group (n = 32) and Pleksor (P) group (n = 27). Plerixafor was administered as a just-in-time approach with granulocyte-colony stimulating factor (G-CSF) alone or with cyclophosphamide (Cy) + G-CSF mobilization. The study aimed to assess mobilization success and engraftment kinetics. There was no statistically significant difference between the two groups in terms of age, gender, RT history, previous lines of treatment, pretransplant lenalidomide cycles (p = 0.778, 0.165, 0.520, 0.094, 0.530, respectively). However, lenalidomide exposure was significantly higher in P group (18,8% vs. 81,5%, p < 0.001). Both groups achieved a similar total yield of CD34 + cells, and no serious side effects related to plerixafor were noted. Median platelet engraftment time was longer in P group, while neutrophil engraftment time was similar in both groups. This study demonstrates the comparable efficacy of generic plerixafor in myeloma patients, suggesting that it can be a cost-effective alternative with a similar safety profile. These findings contribute to the body of evidence on the use of generic plerixafor in specific patient cohorts, emphasizing its efficacy and safety for ASCT in a sole multiple myeloma patient cohort.
dc.identifier.citationYiğit Kaya, S., Mutlu, Y. G., Yücel, O. K., Nizam Özen, İ., Ataş, Ü., Melek, E. ... Sevindik, Ö. G. (2025). Original vs. generic plerixafor for the mobilization of stem cells in multiple myeloma patients. Indian Journal of Hematology and Blood Transfusion, 41(1), 38-42. http://dx.doi.org/10.1007/s12288-024-01841-8
dc.identifier.doi10.1007/s12288-024-01841-8
dc.identifier.endpage42
dc.identifier.issn0971-4502
dc.identifier.issn0974-0449
dc.identifier.issue1
dc.identifier.pmid39917490
dc.identifier.scopus2-s2.0-85201817143
dc.identifier.scopusqualityQ3
dc.identifier.startpage38
dc.identifier.urihttp://dx.doi.org/10.1007/s12288-024-01841-8
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12922
dc.identifier.volume41
dc.identifier.wosWOS:001296516600001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorYiğit Kaya, Süreyya
dc.institutionauthorMutlu, Yaşa Gül
dc.institutionauthorMelek, Elif
dc.institutionauthorMaral, Senem
dc.institutionauthorKaynar, Leylagül
dc.institutionauthorSevindik, Ömür Gökmen
dc.institutionauthorid0000-0002-9005-5587
dc.institutionauthorid0000-0003-4766-1861
dc.institutionauthorid0000-0002-2035-9462
dc.institutionauthorid0000-0001-9636-4113
dc.language.isoen
dc.relation.ispartofIndian Journal of Hematology and Blood Transfusion
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectGeneric
dc.subjectMobilization
dc.subjectMultiple Myeloma
dc.subjectPlerixafor
dc.subjectStem Cell
dc.titleOriginal vs. generic plerixafor for the mobilization of stem cells in multiple myeloma patients
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu